About this episode
Drugs like Ozempic and Zepbound have revolutionized weight loss. And starting next year, the drugs are going to become more affordable for Americans because of a deal struck with pharmaceutical companies by the Trump administration.
Eshe Nelson, who covers economics and business news, explains how the change has its origins in a huge business blunder from the creator of Ozempic, Novo Nordisk.
Guest: Eshe Nelson, a reporter for The New York Times based in London, where she covers economics and business news.
Background reading:
- How Ozempic’s maker lost its shine after creating a wonder drug.
- What Trump’s new drug pricing deal means for people with obesity.
Photo: Sergei Gapon/Agence France-Presse — Getty Images
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time The Daily publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Daily
Naomi Klein and Astra Taylor Say the End of the World is Now on the Table
The Daily
The Lives That 9/11 Keeps Taking
The Daily
A Couple Breaks Up. Who Gets Custody of Their Embryos?
The Daily
Trump’s War on Mail-In Voting
The Daily